Sagimet Biosciences Inc. (SGMT)
$0.00+$0.29 (+2.75%) TodayExtended Hours
David Happel - OfficerDavid Happel - OfficerSagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 464,633 | $4.51M |
| Grant or award | 6 | 237,402 | |
| Option exercise | 8 | 742,386 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
31 Form 4 filings on record, the earliest from Jun 9, 2025, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Elizabeth A. Grammer - Director | Grant or award | Stock Option (Right to Buy) | 32,250 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 31 SGMT filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| GEORGE KEMBLE | Director | 350,987 | $3.26M | View on EDGAR | |
| GEORGE KEMBLE | Director | 20,206 | $193K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Sagimet Biosciences Inc. (SGMT) had 11 insider filings in the last 90 days, with the most recent on 2026-08-17. The full record for SGMT runs to 31 Form 4 filings, the earliest from 2025-06-09. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of SGMT were filed in the last 90 days.
5 insider sales of SGMT were filed in the last 90 days, totaling $4.51M.
This page tracks SGMT Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add SGMT to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
